AlloSeq Tx 17 for transplant matching gets CE mark

June 10, 2020 0 By FM

CareDx, Inc has received the CE mark for AlloSeq Tx 17. AlloSeq Tx 17 is for matching transplant donor organs to recipients, utilising next generation hybrid capture (HC) technology for HLA testing. 

CareDx launched this novel technology during the American Society for Histocompatibility and Immunogenetics (ASHI) and BANFF Foundation for Allograft Pathology’s Joint meeting September 2019.

CareDx, Inc., headquartered in South San Francisco, California, is a leading precision medicine solutions company focused on the discovery, development and commercialization of clinically differentiated healthcare solutions for transplant patients and caregivers.